الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 82 |  |  |
| | | from | 82 | | |
Abstract
Summary One of the most common causes of chronic liver disease is fatty liver disease, and it is on the rise all over the world because of the obesity epidemic. Hepatic steatosis is characterized by a buildup of aberrant and excessive lipids inside the hepatocytes.
The present clinical measurement of liver fat is invasive, includes sample mistakes, and is inadequate for screening, monitoring, and clinical decision making.
Noninvasive approaches for properly and objectively quantifying liver fat are required; fatty liver biopsy may be too painful for many people. Ultrasound (US) and computed tomography (CT) can be used to measure liver fat, but their accuracy and other limitations are restricted.
In clinical practice, MR imaging now provides a reliable and practical approach of quantifying liver fat, particularly for the long-term follow-up of patients with fatty liver disease. MR is an imaging modality (Dixon sequence) that can identify and quantify liver fat level by detecting proton signals in water and fat. This allows for reliable determination of liver fat content.
The goal of this study is to quantify fat deposition in fatty liver patients and compare the results to US findings and laboratory liver function tests such as alanine transaminase (ALT) and aspartate transaminase (AST) .
This prospective research comprised 47 individuals who were referred to the Radiology department, Minia university hospital with clinical diagnosis of fatty liver during the period from December 2020 to November 2021. Approval of the local ethical committee to perform the study was obtained. A written informed consent was taken from all patients after full explanation of the techniques and the aim of the current study.
Subjects:
The 47patients included in the study were divided into 3 groups according to the results of MRI Dixon fat fraction % as following:
o group I MRI Dixon fat was less than 15% (23 patients),
o group II between 15-30% (17 patients)
o group III more than 30% (7 patients).
Exclusion criteria:
1- Patient with kwon malignant hepatic tumors
2- Patient with contra indication to MRI:
o Patient with cochlear implant
o Patient with surgical aneurysmal clip
o Patient with cardiac pace maker
All subjects included in the study were subjected to the following:
oCareful history taking
oUltrasound and MRI examination
o Laboratory investigation included ALT & AST.
The results of this study were summarized as follow:
MRI Dixon fat fraction correlation with serum AST and ALT: in group I there was no statistically significant correlation. All the patients in group I had serum ALT and AST within normal range while the MRI Dixon fat fraction result goes with mild fatty liver infiltration.
In group II there was no statistically significant correlation with serum AST. However, there was a statistically significant correlation with serum ALT.
In group III there was a statistically non- significant correlation between Dixon fat fraction result with serum AST and serum ALT